ACOG Alpha Cognition Inc.
Alpha Cognition Inc. (ACOG) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.32 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -5.4% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Alpha Cognition Inc.
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.
Sector
Healthcare
Industry
Biotechnology